Biotech companies developing novel molecules need significant funding, but it’s becoming harder to raise money. Venture capitalists are being more selective, focusing on companies with strong clinical data, large market potential, and experienced teams. The days of easy money and IPOs based on stories are gone, leading to collaboration with big pharma for not just capital but also expertise. To stand out in crowded therapeutic areas, companies must show differentiation. Investors are now looking at a broader landscape of opportunities, with interest shifting from cancer to immunology and CNS disorders. The key to attracting investment includes having the right data, a large market, and a proven team.
Source link
Two Venture Investors Offer Their Takes on the State of Biotech Investing Today
